AlzBiomarker

Primary Progressive Aphasia (Logopenic Variant) vs Alzheimer's Disease: Aβ42 (CSF)

Tools

Back to the Top

Meta-analysis did not show a diffrence in the levels of Aβ42 in the cerebrospinal fluid of people with logopenic variant primary progressive aphasia and people with Alzheimer's disease. However, a paucity of data limited the meta-analysis, with only two eligible studies and a small number of individuals with lvPPA. For comparison, the level of Aβ42 in the CSF of control subjects is nearly double that of people with Alzheimer's disease. The decrease in Aβ42 in the CSF of AD patients is thought to reflect the deposition of the peptide into amyloid plaques in the brain; notably, lvPPA has also been associated with amyloid deposition (Mesulam et al., 2008; Rabinovici et al., 2008).

Loading data...

How to interpret a forest plot: Each individual effect size (ES) is a ratio of the mean biomarker level in one condition over the mean level in another condition. An ES equal to 1 means that the two conditions had identical mean values. An ES > 1 indicates higher levels in the first condition, whereas an ES < 1 indicates lower levels in the first condition. The overall ES, indicated by a black diamond, is a weighted average of the individual effect sizes. The weight of each data point was determined by the inverse of the variance and is reflected in the size of each square. The width of the overall ES diamond is determined by the 95 percent confidence interval. Data out of range of the scale, including ES and confidence intervals, are indicated by an arrowhead at the edge of the plot, when applicable. 

Version 3.0, July 2021.